Arvee Laboratories (India) Ltd. Overview
Arvee Laboratories is a Gujarat-based, promoter-controlled manufacturer of niche aromatic and heterocyclic fine chemicals, operating a single multi-purpose batch plant near Bhavnagar. Its portfolio spans three application families: sulfonated isophthalic "polymer modifiers" (sodium and lithium salts of 5-sulfoisophthalic acid and their esters) that impart cationic dyeability and water dispersibility to polyester fibres, films and resins; nitro-, amino- and hydroxy-isophthalic "contrast media intermediates" that sit upstream of iodinated X-ray/CT contrast agents; and thiophene- and pyridine-based "drug intermediates". The business is small (FY2026 revenue INR 31.5 crore), volatile (revenue has swung between INR 30 crore and INR 61 crore over four years), nearly debt-free, and increasingly export-oriented, with foreign-exchange earnings equal to roughly 28% of FY2026 revenue. A record Q1 FY2027 (revenue INR 17.2 crore) has re-rated the stock, but the company remains a thinly traded, uncovered nano-cap with a non-cooperating credit rating and limited disclosure.
What the company does
Arvee Laboratories manufactures and sells specialty and intermediate chemicals produced by multi-step batch synthesis. The company's own statutory description is brief: its FY2026 Board's Report states only that the company "is engaged in Chemicals" and that there has been no change in the nature of business. The segment note in its Q1 FY2027 results describes operations as falling within the chemicals business, now reported across two segments — a "Textile Chemical Segment (Films & Fibre)" and a "Non-textile Segment" (FY2026 integrated filing marked "Multi segment"; Q1 FY2027 segment table).
Data vendors that summarise its filings (Morningstar, Wright Research, Musaffa) characterise Arvee as a specialty chemical company organised around three product families — polymer modifiers, contrast media intermediates and drug intermediates — and note that it principally operates in India by location of assets, although its FY2026 foreign-exchange earnings show that a material share of sales is now exported.
Chemistry and manufacturing capability
The company's website lists the unit processes its Bhavnagar plant is equipped to run: nitration, sulfonation, reduction (including catalytic reduction), halogenation, esterification, alkylation, acylation, Hofmann reaction, Grignard reaction, Vilsmeier–Haack reaction, Sandmeyer reaction, caustic fusion and Friedel–Crafts reaction. Equipment disclosed on the website includes approximately 80,000 litres of glass-lined reactor capacity (individual vessels from 1 KL to 6.3 KL), approximately 35,000 litres of stainless-steel reactor capacity (0.5 KL to 6.5 KL), more than 8,500 litres of simultaneous centrifugation capacity, more than 6,000 litres of agitated Nutsche filtration capacity, stainless-steel distillation columns, and rotocone vacuum, fluidised-bed and tray dryers, supported by boilers, chilling and brine plants, cooling towers, power generation, DM water, vacuum systems and an effluent treatment plant.
This is the profile of a classic Indian "multi-purpose intermediates" plant: a modest total reactor volume (roughly 115 KL) that can be re-configured across many chemistries, which allows a broad catalogue but limits scale economics in any single molecule.
Business and revenue model
| Revenue model component | Assessment | Basis |
|---|---|---|
| Product sales (manufactured goods) | Essentially 100% of revenue | All reported revenue is "revenue from operations" from chemical sales; no service, licensing or subscription revenue is disclosed |
| Services / tolling / custom synthesis | — | The company's origins involved job-work arrangements (see Section 3), but no current tolling revenue is reported |
| Licensing / royalties | None disclosed | — |
| Subscription | Not applicable | — |
| Other income | INR 0.69 crore in FY2026 (about 2% of revenue) | FY2026 Annual Report |
Sales are business-to-business, made to manufacturers rather than end consumers. Pricing is not disclosed; as a commodity-linked intermediate producer, pricing is likely negotiated per order or per contract with exposure to input-cost pass-through, but this is an analytical inference, not a disclosed fact.
Value-chain position
Arvee sits in the middle of the chemical value chain. Upstream, it buys aromatic and heterocyclic feedstocks (isophthalic acid derivatives, thiophene, pyridine and related raw materials, plus acids, alkalis and solvents); its FY2026 foreign-exchange outgo on imported raw materials was INR 7.38 crore against total raw material consumption of INR 18.19 crore, implying that roughly 41% of materials consumed by value were imported (FY2026 Annual Report; analytical calculation). Downstream, its outputs are consumed by:
-
polyester fibre, film and resin producers (polymer modifiers for cationic-dyeable polyester, water-dispersible polyester, textile sizing, spin finishes);
-
manufacturers of iodinated contrast media active ingredients, through their intermediate supply chains (contrast media intermediates);
-
pharmaceutical API and advanced-intermediate manufacturers (drug intermediates);
-
per CRISIL, also customers in fertiliser and "other" industries.
Customer types and end-markets
| End-market | Products relevant | Disclosure status |
|---|---|---|
| Textiles / polyester fibres and films | DMS/Na-SIPA/Li-SIPA/SIPHE-40 polymer modifiers | Named application areas disclosed (prospectus, website); customer names not disclosed |
| Medical imaging (iodinated contrast agents) | 5-NIPA, DM-5-NIPA, MM-5-NIPA, 5-AIPA, dimethyl 5-AIPA, 5-HIPA, 3,5-DNBA, 3,5-diaminobenzoic acid | Application disclosed; customer names not disclosed |
| Pharmaceuticals | 2-acetylthiophene, thiophene-2-carboxaldehyde, 4-aminopyridine, 2-chloro-5-nitrobenzoic acid | Application disclosed; customer names not disclosed |
| Fertilisers and other | Not specified | CRISIL description |
Customer concentration: not publicly disclosed in the sources reviewed. Given the company's size and the niche nature of each molecule, meaningful concentration is likely, but no figures are published.
Independent characterisation
Arvee is best characterised as a sub-scale, owner-managed, multi-product intermediates manufacturer whose earnings are highly sensitive to a small number of orders and to working-capital swings. Its competitive "moat", to the extent one exists, lies in process know-how for a set of low-volume molecules (notably SIPA salts and nitro-isophthalic contrast-media precursors) where global buyer pools are concentrated and qualification cycles create some stickiness. Against that, there is no disclosed R&D spend, no patent portfolio, a single plant, and a revenue history that has gone sideways for nearly a decade (FY2016 revenue INR 26.8 crore; FY2026 revenue INR 31.5 crore; ten-year sales CAGR of about 2% per Screener).
Strategy
Stated corporate strategy
Arvee publishes no formal strategy document, investor presentation or medium-term plan, and holds no investor days or earnings calls. The only strategy-relevant statements found in disclosures are:
Mission themes (website): The company's tagline is "Delivering Quality, Thinking Safety, Preserving Nature", and its website describes an aspiration to be a leading chemical manufacturer offering good-quality, innovative products at competitive prices, with an eco-friendly orientation.
Diversification (prospectus-era, per IIFL summary): The promoters aimed to diversify into specialty chemicals such as dimethyl 5-nitroisophthalate, thiophene-2-carboxaldehyde, 2-acetylthiophene and lithium sulfoisophthalic acid (LiSIPA) serving Indian and overseas customers — products that are now in the catalogue.
FY2026 Board's Report: States that the company "is taking all the possible steps to increase the profitability" and, on dividends, that resources are being conserved. No specific initiatives are named.
Initiatives in the last 24 months
| Date | Initiative | Status / detail | Source |
|---|---|---|---|
| FY2025–FY2026 | Capex: net fixed assets rose from INR 12.67 crore (FY2024) to INR 16.72 crore (FY2026); implied capex ~INR 4.7 crore over two years | Nature of capex not disclosed (likely debottlenecking/maintenance) | Screener |
| FY2026 | Export push: export receipts +40%; export sales commission nearly tripled | Implies use of overseas agents | FY2026 Annual Report |
| FY2026 | Investment of INR 1.70 crore appears on balance sheet (first since FY2021) | Nature not disclosed | Screener |
| FY2026 / Q1 FY2027 | Segment re-organisation: two segments (Textile Films & Fibre vs Non-textile) introduced, with transfer of assets from Textile to Non-textile | Implemented in Q1 FY2027 reporting | Q1 FY2027 results |
| 2026 (before 7 Aug) | Scheme of Arrangement proposed | On 7 Aug 2026, the board "decided to postpone the Scheme of arrangement for better understanding of the matter". Nature (demerger, merger, capital reorganisation, etc.), counterparties and terms are not publicly disclosed in sources reviewed | Board outcome 7 Aug 2026 |
| Ongoing | Energy conservation: LED lighting installed; no alternative-energy or energy-capex initiatives | FY2026 Board's Report | FY2026 Annual Report |
Transformation, cost programmes, ESG commitments
None announced. No sustainability targets, cost-reduction programmes with numeric targets, or digital/platform investments have been disclosed.
Management guidance / medium-term targets
Not publicly disclosed. The company provides no revenue, margin or capex guidance.
Products & Services
The catalogue below is compiled from the company website product menu, the IPO prospectus (as summarised by Screener), and data-vendor descriptions. Specifications, launch years and pricing are not publicly disclosed for any product unless noted; target customers are described by application. Applications for polymer modifiers are as stated in the prospectus; other applications reflect well-established industry uses of these molecules.
Polymer Modifiers (likely mapped to Textile Chemical Segment)
| Product | Abbreviation | Description / function | Target customer | Launch year | Pricing |
|---|---|---|---|---|---|
| Dimethyl 5-sodiosulfoisophthalate | DMS salt (also DCBMS salt per prospectus) | Sulfonated isophthalate ester co-monomer; introduces anionic sulfonate sites into polyester chains to make them dyeable with cationic (basic) dyes | Polyester fibre and yarn producers | — | — |
| 5-Sulfoisophthalic acid monosodium salt | Na-SIPA | Acid-form co-monomer for cationic-dyeable polyester and water-dispersible polyester resins | Polyester fibre, resin and coating producers | — | — |
| 5-Sulfoisophthalic acid monolithium salt | Li-SIPA | Lithium analogue of SIPA, used where lithium counter-ion is preferred (e.g., certain polyester and specialty polymer formulations); prospectus also lists LiSIPA among diversification targets | Polyester / specialty polymer producers | — | — |
| 5-Sodiosulfo-bis-(β-hydroxyethyl)-isophthalate | SIPHE-40 | Glycol ester (typically supplied as a solution) for direct incorporation into polyester polymerisation | Polyester polymer producers | — | — |
Prospectus-listed applications for the family: cationic dyeability of polyester, water-soluble/dispersible polyester resins, textile sizing and coatings, and synthetic-fibre spin finishes.
Contrast Media Intermediates (likely mapped to Non-textile Segment)
| Product | Abbreviation | Description / function | Target customer |
|---|---|---|---|
| 5-Nitroisophthalic acid | 5-NIPA | Nitration product of isophthalic acid; key building block toward 5-aminoisophthalic acid derivatives used in iodinated contrast agents | Contrast-media API makers and their intermediate suppliers |
| Dimethyl 5-nitroisophthalate | DM-5-NIPA | Esterified 5-NIPA; precursor to dimethyl 5-aminoisophthalate | Same |
| Monomethyl 5-nitroisophthalate | MM-5-NIPA | Mono-ester variant used in alternative synthetic routes | Same |
| 5-Hydroxyisophthalic acid | 5-HIPA | Hydroxylated isophthalic acid (also used in polymer and specialty applications) | Contrast-media and specialty chemical makers |
| 5-Aminoisophthalic acid | 5-AIPA | Reduction product of 5-NIPA; core scaffold for tri-iodinated benzene contrast agents | Contrast-media API makers |
| Dimethyl 5-aminoisophthalate | ATIPA (website code) | Ester of 5-AIPA; downstream intermediate | Contrast-media API makers |
| 3,5-Dinitrobenzoic acid | 3,5-DNBA | Dinitrated benzoic acid; precursor to 3,5-diaminobenzoic acid | Contrast-media and dye/pharma makers |
| 3,5-Diaminobenzoic acid | (ATIPA-CL page on website) | Reduction product of 3,5-DNBA; a building block for diatrizoate-type contrast agents and specialty polymers | Contrast-media and polymer makers |
Drug Intermediates (likely mapped to Non-textile Segment)
| Product | Description / function | Target customer | Note |
|---|---|---|---|
| 2-Acetylthiophene | Thiophene ketone used as a pharmaceutical building block | API / advanced-intermediate makers | Thiophene-derivative plant was the company's first, commissioned 2013 |
| Thiophene-2-carboxaldehyde | Thiophene aldehyde used in pharmaceutical and agrochemical synthesis | API makers | Same plant lineage; prospectus listed it as a diversification focus |
| 4-Aminopyridine | Pyridine amine used as a pharmaceutical intermediate (and as an API in some markets) | Pharmaceutical makers | — |
| 2-Chloro-5-nitrobenzoic acid | Halogenated nitro-aromatic acid used as an intermediate | Pharma / dye makers | — |
Services
No services, toll manufacturing or custom synthesis offerings are separately marketed on the website or disclosed in filings. Not publicly disclosed.
Portfolio observations
The catalogue has been essentially static: the same 16 products appear in the 2018 prospectus summary and on the 2026 website. No new product launches have been announced in the last 24 months in any filing reviewed. The breadth (16 molecules across 3 families) relative to revenue (~INR 31–41 crore) implies average revenue per product of only about INR 2–2.5 crore, consistent with a niche, campaign-based batch producer.
Financial Narrative
Sources: Screener.in standardised standalone financials (data by C-MOTS, derived from company annual reports) for FY2022–FY2026; FY2025 and FY2026 Board's Reports; Q1 FY2027 results. Ratios marked "calc." are computed by the analyst from the reported figures. All figures INR crore unless stated.
Income statement
Notes:
-
Diluted EPS equals basic EPS; the company has no convertible instruments or ESOPs (FY2026 Annual Report). The company's own FY2026 results show EPS of INR 2.29, a rounding difference from Screener's INR 2.30.
-
FY2025 figures per the Board's Report: revenue INR 384,872 thousand, PBT INR 28,708 thousand, PAT INR 21,473 thousand. FY2026: revenue INR 315,141 thousand, PBT INR 24,304 thousand, tax credit INR 959 thousand, PAT INR 25,263 thousand.
Gross profit (where derivable)
Arvee does not report gross profit. A materials-based gross margin can be derived only where the full expense breakdown was retrieved:
FY2022–FY2025 gross profit: not publicly disclosed in the sources reviewed. The swing between FY2026 (inventory build of INR 3.5 crore credited to P&L) and Q1 FY2027 (inventory drawdown of INR 2.1 crore debited) shows that reported gross margin is heavily affected by inventory timing; a "true" run-rate gross margin likely lies between the two.
Margins and growth
Revenue CAGR FY2022–FY2026 (4 years, calc.): approximately −6.0% per year. Screener reports 5-year sales CAGR of −8% and 3-year of −20%, and TTM growth of +17%.
Commentary. The five-year record is one of high volatility around a flat-to-declining trend. FY2023 was an outlier year — revenue rose 52% to INR 61.35 crore and ROCE peaked at 23% — most plausibly driven by an unusually large order book in one or more product families (the company has not explained the spike in the materials reviewed). FY2024 then saw revenue halve to INR 30.35 crore, with EBITDA margins compressing below 10% as fixed costs were spread over a smaller base and the tax rate spiked to 42.6% (Q4 FY2024 alone carried an 81% tax rate on a small profit base). FY2025 recovered partially (+26.8%) on strong H1 sales (Q1 and Q2 FY2025 revenue of INR 10.6 crore and INR 12.5 crore), but the second half was weak, with Q4 FY2025 EBITDA margin at only 3.4%. FY2026 was a second down year (−18%), with Q2 FY2026 revenue collapsing to INR 3.45 crore — the lowest quarterly figure in at least three years — before a sharp H2 recovery.
Net income in FY2026 (+17.7%) outpaced pre-tax income (−15%) solely because of a net tax credit of INR 0.96 crore, driven by a deferred-tax credit of INR 0.47 crore and a Q3 FY2026 negative tax charge. Net margin of 8.0% in FY2026 is therefore flattered and should not be treated as a run-rate.
Depreciation has fallen from INR 2.3 crore to INR 1.2 crore over five years as older assets became fully depreciated, which has mechanically supported EBIT margins despite weaker EBITDA margins.
Quarterly trend (13 quarters)
(Source: Screener.in quarterly standalone data; Q1 FY2027 cross-checked to the company's 7 August 2026 filing: revenue INR 1,722.53 lakh, PBT INR 228.88 lakh, PAT INR 169.41 lakh, EPS INR 1.54.)
Inflection. The three most recent quarters show a clear upturn: revenue of INR 9.78 crore, INR 10.80 crore and INR 17.23 crore, with Q1 FY2027 the highest quarterly revenue in the 13-quarter window and the highest EBITDA (INR 2.49 crore). Q1 FY2027 revenue was up 130% YoY and 59% QoQ. Trailing-twelve-month (Q2 FY2026–Q1 FY2027) revenue is INR 41.26 crore and TTM net income INR 4.05 crore (EPS about INR 3.67). However, Q1 FY2027 cost structure shows a INR 2.08 crore inventory drawdown, meaning part of the revenue surge was met from stock built in FY2026 rather than new production; sustainability will depend on order inflows in Q2 and Q3 FY2027.
Balance sheet
Notes and gaps:
- Goodwill and intangibles: none disclosed (no acquisitions accounted for as business combinations).
Short-term vs long-term debt split: not disclosed in the standardised data. CRISIL's rating covers INR 5.50 crore of cash credit (short-term working capital), INR 4.06 crore of term loan and INR 4.44 crore of proposed long-term facilities — these are sanctioned limits, not outstanding balances. Outstanding borrowings were only INR 1.11 crore at 31 March 2026.
Cash & equivalents, net debt, working capital: cash balances were not disclosed in the sources reviewed, so net debt and precise working capital cannot be computed.
-
Other equity at 30 June 2026 was INR 24.46 crore (Q1 FY2027 filing), taking net worth to about INR 35.6 crore (book value ~INR 32.3 per share; Screener shows INR 30.7 based on 31 March 2026).
-
FY2026 retained earnings rose from INR 18.31 crore to INR 20.83 crore; securities premium was unchanged at INR 1.94 crore (FY2026 Board's Report).
Cash flow
Commentary. Cash conversion is the weakest part of the financial profile. Over FY2022–FY2026, cumulative net income was INR 12.4 crore but cumulative operating cash flow only INR 6.9 crore and cumulative free cash flow −INR 4.2 crore. In FY2025 and FY2026 combined, the company reported INR 4.7 crore of profit but negative operating cash flow, as receivables and inventory absorbed cash (debtor days rose from 73 to 121; inventory days from 80 to 229 between FY2025 and FY2026). The positive FY2026 investing cash flow (+INR 0.50 crore) despite ~INR 2.8 crore of capex suggests asset or investment disposals/other investing inflows, but the breakdown was not disclosed in the materials reviewed. Financing outflows since FY2022 have been minimal, reflecting completion of the deleveraging that began in FY2019.
Ratios
Not computable from sources reviewed: current ratio and net debt / EBITDA (cash and current-asset/current-liability splits not disclosed). ROIC is not reported; ROCE is used as a proxy.
Commentary. Returns are mediocre outside FY2023: average ROE across FY2024–FY2026 is about 6%, below any reasonable cost of equity for an illiquid nano-cap. Leverage is negligible and interest coverage comfortable. The single most important negative trend is the deterioration in the cash conversion cycle, which has more than quadrupled from 42 days (FY2023) to 191 days (FY2026). Some of this is the arithmetic effect of a revenue dip on year-end balances, and Q1 FY2027's inventory drawdown suggests partial reversal is under way, but the trend warrants close monitoring.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains (analyst mapping) | Products (analyst mapping; company does not publish a product-to-segment map) |
|---|---|---|
Textile Chemical Segment (Films & Fibre) | Polymer modifiers sold into polyester fibre and film applications | DMS salt, Na-SIPA, Li-SIPA, SIPHE-40 (likely) |
Non-textile Segment | Contrast media intermediates, drug intermediates and other non-textile chemicals | 5-NIPA family, 5-AIPA family, 5-HIPA, 3,5-DNBA, 3,5-diaminobenzoic acid, thiophene derivatives, 4-aminopyridine, 2-chloro-5-nitrobenzoic acid |
Metric (INR Lakh, Q1 FY2027, Quarter Ended 30 Jun 2026) Details
| Metric (INR Lakh, Q1 FY2027, quarter ended 30 Jun 2026) | Textile (Films & Fibre) | Non-textile | Total |
|---|---|---|---|
Segment revenue (incl. other income) | 230.58 | 1,510.03 | 1,740.61 |
Share of total revenue | 13.2% | 86.8% | 100% |
Segment result (PBIT) | 29.99 | 204.96 | 234.95 |
Segment PBIT margin | 13.0% | 13.6% | 13.5% |
Capital employed | 422.80 | 3,154.80 | 3,577.60 |
Annualised segment pre-tax return on capital employed (analyst calc., ×4) | 28.4% | 26.0% | 26.3% |
Segment revenue (INR Cr)
| Segment revenue (INR Cr) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue from operations | 30.35 | 38.49 | 31.51 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 40.33 | 61.35 | 30.35 | 38.49 | 31.51 |
Total operating expenses (INR Cr) | 34.65 | 54.06 | 27.41 | 34.88 | 28.33 |
EBITDA excl. other income (INR Cr) | 5.68 | 7.29 | 2.94 | 3.61 | 3.18 |
Other income (INR Cr) | 0.46 | 1.35 | 0.64 | 0.66 | 0.69 |
Depreciation (INR Cr) | 2.32 | 2.08 | 1.50 | 1.15 | 1.21 |
Operating income EBIT incl. other income (INR Cr, calc.) | 3.82 | 6.56 | 2.08 | 3.12 | 2.66 |
Interest expense (INR Cr) | 0.37 | 0.39 | 0.25 | 0.25 | 0.23 |
Pre-tax income (INR Cr) | 3.45 | 6.17 | 1.83 | 2.87 | 2.43 |
Effective tax rate (%) | 25.51 | 33.23 | 42.62 | 25.09 | -3.70 |
Net income (INR Cr) | 2.57 | 4.12 | 1.05 | 2.15 | 2.53 |
EPS basic (INR) | 2.33 | 3.74 | 0.95 | 1.95 | 2.30 |
EPS diluted (INR) | 2.33 | 3.74 | 0.95 | 1.95 | 2.30 |
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue History
| Period | Revenue (INR Lakh) | Cost of materials consumed (INR Lakh) | Change in inventories (INR Lakh) | Materials gross profit (INR Lakh, calc.) | Materials gross margin |
|---|---|---|---|---|---|
FY2026 | 3,151.41 | 1,818.90 | -352.53 | 1,685.04 | 53.5% |
Q1 FY2027 | 1,722.53 | 916.64 | 207.83 | 598.06 | 34.7% |
Q1 FY2026 | 748.00 | 548.27 | -206.34 | 406.07 | 54.3% |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin excl. other income (%) | 14.08 | 11.88 | 9.69 | 9.38 | 10.09 |
EBIT margin incl. other income (%, calc.) | 9.47 | 10.69 | 6.85 | 8.11 | 8.44 |
Pre-tax margin (%, calc.) | 8.55 | 10.06 | 6.03 | 7.46 | 7.71 |
Net margin (%, calc.) | 6.37 | 6.72 | 3.46 | 5.59 | 8.03 |
Revenue growth YoY (%, calc.) | -14.88 | 52.12 | -50.53 | 26.82 | -18.13 |
Net income growth YoY (%, calc.) | -4.10 | 60.31 | -74.51 | 104.76 | 17.67 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (INR Cr) | 7.60 | 8.91 | 7.70 | 6.14 | 10.60 | 12.53 | 8.91 | 6.45 | 7.48 | 3.45 | 9.78 | 10.80 | 17.23 |
EBITDA excl. other income (INR Cr) | 0.98 | 0.69 | 0.53 | 0.79 | 1.54 | 1.50 | 0.34 | 0.22 | 0.34 | 0.12 | 1.63 | 1.10 | 2.49 |
EBITDA margin (%) | 12.89 | 7.74 | 6.88 | 12.87 | 14.53 | 11.97 | 3.82 | 3.41 | 4.55 | 3.48 | 16.67 | 10.19 | 14.45 |
Pre-tax income (INR Cr) | 0.65 | 0.28 | 0.32 | 0.58 | 1.26 | 1.31 | 0.20 | 0.09 | 0.18 | 0.01 | 1.40 | 0.86 | 2.29 |
Net income (INR Cr) | 0.49 | 0.21 | 0.24 | 0.12 | 0.94 | 0.98 | 0.15 | 0.07 | 0.17 | 0.01 | 1.83 | 0.52 | 1.69 |
EPS (INR) | 0.44 | 0.19 | 0.22 | 0.11 | 0.85 | 0.89 | 0.14 | 0.06 | 0.15 | 0.01 | 1.66 | 0.47 | 1.53 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity share capital (INR Cr) | 11.02 | 11.02 | 11.02 | 11.02 | 11.02 |
Reserves / other equity (INR Cr) | 12.92 | 17.04 | 18.09 | 20.24 | 22.77 |
Total shareholders' equity (INR Cr) | 23.94 | 28.06 | 29.11 | 31.26 | 33.79 |
Total borrowings (INR Cr) | 3.13 | 1.00 | 1.00 | 1.03 | 1.11 |
Other liabilities (INR Cr) | 11.61 | 9.63 | 8.45 | 5.29 | 7.99 |
Total assets (INR Cr) | 38.68 | 38.69 | 38.56 | 37.58 | 42.89 |
Net fixed assets (INR Cr) | 13.84 | 12.68 | 12.67 | 15.27 | 16.72 |
Capital work in progress (INR Cr) | 0.98 | 1.53 | 2.62 | 0.73 | 0.90 |
Investments (INR Cr) | 0 | 0 | 0 | 0 | 1.70 |
Other assets incl. current assets (INR Cr) | 23.86 | 24.48 | 23.27 | 21.58 | 23.57 |
Goodwill & intangibles (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities (INR Cr) | 0.68 | 2.93 | 3.66 | -0.21 | -0.12 |
Cash from investing activities (INR Cr) | 0.06 | -1.26 | -2.16 | -1.32 | 0.50 |
Cash from financing activities (INR Cr) | -6.06 | -2.42 | -0.19 | -0.12 | -0.16 |
Net cash flow (INR Cr) | -5.32 | -0.75 | 1.31 | -1.64 | 0.23 |
Implied capex (INR Cr, CFO minus FCF) | 2.36 | 1.46 | 2.59 | 1.85 | 2.83 |
Free cash flow (INR Cr) | -1.68 | 1.47 | 1.07 | -2.06 | -2.95 |
Dividends paid (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
CFO / EBITDA (%) | 29 | 64 | 139 | 10 | 3 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%, calc.) | 11.3 | 15.8 | 3.7 | 7.1 | 7.8 |
ROA on average assets (%, calc.) | 6.4 | 10.7 | 2.7 | 5.6 | 6.3 |
ROCE (%, Screener; proxy for ROIC) | 12.89 | 23.34 | 6.83 | 9.58 | 7.53 |
Debt / equity (x, calc.) | 0.13 | 0.04 | 0.03 | 0.03 | 0.03 |
Gross debt / EBITDA (x, calc.) | 0.55 | 0.14 | 0.34 | 0.29 | 0.35 |
Interest coverage EBIT / interest (x, calc.) | 10.3 | 16.8 | 8.3 | 12.5 | 11.6 |
Asset turnover on average assets (x, calc.) | 1.01 | 1.59 | 0.79 | 1.01 | 0.78 |
Debtor days | 109.78 | 72.94 | 73.48 | 79.66 | 121.05 |
Inventory days | 93.24 | 42.29 | 159.02 | 80.31 | 228.81 |
Payable days | 160.12 | 73.30 | 164.49 | 57.72 | 159.35 |
Cash conversion cycle (days) | 42.90 | 41.94 | 68.01 | 102.25 | 190.51 |
Working capital days | 49.96 | 70.44 | 95.97 | 103.55 | 168.43 |
Revenue by Region
| Geography (INR Cr, cash-basis proxy) | FY2025 | FY2026 |
|---|---|---|
Export receipts (foreign exchange earnings) | 6.26 | 8.75 |
Domestic revenue (derived: revenue less export receipts) | 32.23 | 22.76 |
Total revenue from operations | 38.49 | 31.51 |
Export receipts as % of revenue | 16.3 | 27.8 |
Revenue by Region by Outflow
| Outflow (INR Cr) | FY2025 | FY2026 |
|---|---|---|
Imported raw materials | 7.57 | 7.38 |
Export sales commission | 0.08 | 0.22 |
Valuation Snapshot
| Metric | Value | Source |
|---|---|---|
Last close (19 Oct 2026) | INR 209 (−7.48% on the day) | Screener |
52-week high / low | INR 291 / INR 129 | Screener |
1-year price CAGR | ~30% | Screener (19 Oct 2026) |
3-year price CAGR | ~22% | Screener |
5-year price CAGR | ~19% | Screener |
IPO price (Feb 2018) | INR 61 (≈INR 30.5 bonus-adjusted); current price ≈6.9x bonus-adjusted IPO price | IPO records; calc. |
Historical 5-year high | ~INR 315 (per Equentis, as of Apr 2026) | Equentis |
Valuation Multiples
| Multiple | Arvee | Basis |
|---|---|---|
Market capitalisation | INR 231 crore | 1.102 crore shares × INR 209 |
P/E (TTM) | ~56.9x | TTM EPS ~INR 3.67 (Screener) |
P/E (FY2026 EPS INR 2.30) | ~91x | calc. |
P/B | ~6.8x | Book value INR 30.7 per share at 31 Mar 2026 (Screener) |
EV (approx.) | ~INR 232 crore upper bound | Market cap + debt INR 1.11 crore; cash not disclosed (would reduce EV) |
EV/Sales (TTM) | ~5.6x | TTM revenue INR 41.26 crore |
EV/EBITDA (TTM) | ~43x | TTM EBITDA INR 5.34 crore |
Dividend yield | 0% | — |
Peer median P/E / P/B (Value Research, Apr 2026) | ~36.7x / ~2.2x | Value Research |
Capital Markets
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 0 | 0 | 0 | 0 | 0 |
Dividend payout (%) | 0 | 0 | 0 | 0 | 0 |
Action by Date
| Date | Action | Detail |
|---|---|---|
22 Feb 2018 | IPO / listing | 14.6 lakh shares at INR 61; NSE Emerge |
13–15 Oct 2020 | Bonus issue 1:1 | 55.10 lakh bonus shares allotted; capital INR 5.51 crore → INR 11.02 crore |
FY2021–FY2022 | Migration to NSE Main Board | Board approval 10 Oct 2020 |
Credit Ratings
| Agency | Rating | Outlook | Instruments | Date | Note |
|---|---|---|---|---|---|
CRISIL Ratings | B- | Stable | INR 14 crore long-term bank facilities: cash credit INR 5.50 crore; term loan INR 4.06 crore; proposed long-term facility INR 4.44 crore | 27 Feb 2026 (also 27 Dec 2024, 31 Oct 2023) | "Issuer Not Cooperating" — rating based on best-available information; company did not provide information or No Default Statements despite repeated requests |
Moody's / S&P / Fitch | Not rated | — | — | — | — |
Analyst Conclusions
Management guidance
None provided. No earnings calls, investor presentations or quantitative guidance exist.
Consensus expectations
None available (no coverage).
Bull case
-
Earnings inflection is real and operating leverage is high. Revenue rose sequentially for three quarters to a record INR 17.23 crore in Q1 FY2027, with PBT of INR 2.29 crore — more than the entire FY2024 PBT (INR 1.83 crore). If even half of Q1's run-rate persists, FY2027 could deliver the company's best year since FY2023.
-
Export mix shift improves quality of demand. Export receipts grew 40% in FY2026 to ~28% of revenue while domestic sales shrank; export-led growth in qualification-gated contrast-media and pharma intermediates may be stickier than domestic textile demand.
-
Balance-sheet optionality. With near-zero debt, INR 33.8 crore of equity and the INR 3.5 crore inventory build of FY2026 now unwinding, working-capital release could fund growth capex or the proposed restructuring without dilution.
Bear case
-
History of mean reversion. FY2023's record was followed by a 50% revenue collapse; Q1–Q2 FY2025 strength was followed by a weak H2. Q1 FY2027 was partly served from inventory (INR 2.08 crore drawdown), so production-backed demand may be lower than headline revenue implies.
-
Cash does not follow profits. Two consecutive years of negative operating cash flow and a 191-day cash conversion cycle mean reported earnings have not translated into shareholder cash; no dividends have ever been paid.
-
Valuation and governance discount not reflected. At ~57x TTM earnings and ~6.8x book — well above the specialty-chemicals peer medians of ~37x and ~2.2x — the stock prices in sustained growth from a company with zero R&D, a single plant, a static catalogue, non-cooperation with its credit rater, recent listing-compliance lapses and an unexplained, postponed restructuring.
Key catalysts and monitorables (next 12 months)
| # | Catalyst / monitorable | Timing | What to watch |
|---|---|---|---|
| 1 | Q2 FY2027 results | 3 Nov 2026 | Whether revenue holds above INR 10 crore and margins above 12%; segment split trend |
| 2 | Q3 FY2027 results | ~Feb 2027 | Sustainability of the recovery beyond one strong quarter |
| 3 | Scheme of Arrangement | Undetermined | Revival, terms, nature (demerger/merger), valuation and minority-shareholder impact |
| 4 | Working capital | H1 FY2027 balance sheet (Nov 2026) | Reduction in inventory and receivable days; CFO turning positive |
| 5 | CRISIL engagement | Next review (~late 2026/early 2027) | Whether the company cooperates and the INC tag is removed |
| 6 | Export disclosures | FY2027 Annual Report | Export share, destination markets, customer additions |
| 7 | Compliance record | Ongoing | Absence of further NSE fines or late disclosures |
| 8 | Capex / capacity | Ongoing | Any announced expansion, new molecules or R&D investment |
| 9 | Related-party transactions | FY2027 Annual Report (note 35) | Magnitude of rent, consultancy and purchase transactions with promoter entities |
| 10 | Share liquidity | Ongoing | Shareholder base growth; any institutional entry |
Analyst verdict
Arvee Laboratories is a genuine but very small specialty-intermediates manufacturer whose investment case rests almost entirely on whether its recent operating upturn is durable. The positives are tangible: a versatile multi-chemistry plant, a debt-free balance sheet, a portfolio of qualification-gated contrast-media and pharmaceutical intermediates, an export business that grew 40% last year, and a record Q1 FY2027 in which a single quarter generated more pre-tax profit than all of FY2024. Operating leverage is evident — when volumes arrive, incremental margins are high.
The negatives, however, are structural rather than cyclical. Revenue in FY2026 was lower than in FY2018; the product catalogue has not changed in eight years; R&D spending is reported as nil; and the business has repeatedly followed strong periods with sharp reversals. Earnings have not converted into cash for two consecutive years, the cash conversion cycle has stretched to roughly six months, and no dividend has ever been paid. Governance and disclosure fall short of institutional standards: the company does not cooperate with its credit-rating agency, received a secretarial audit observation and an NSE fine within the last year, publishes internally inconsistent segment and committee disclosures, transacts routinely with promoter-owned entities, and has proposed — then postponed without explanation — a Scheme of Arrangement whose terms remain undisclosed.
At roughly 57 times trailing earnings and nearly seven times book value, the market is already capitalising a sustained recovery. For that valuation to be justified, Arvee would need to show at least three further quarters of revenue above INR 10 crore with positive operating cash flow, clarify the restructuring, and improve disclosure. Until such evidence emerges, the stock is best regarded as a high-risk, event-driven nano-cap.
APPENDIX A — LONG-RUN HISTORICAL SERIES (FY2016–FY2021)
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 26.82 | 34.44 | 47.78 | 54.90 | 45.42 | 47.38 |
| EBITDA excl. other income (INR Cr) | 4.99 | 5.90 | 7.17 | 6.17 | 6.02 | 6.07 |
| EBITDA margin (%) | 18.61 | 17.13 | 15.01 | 11.24 | 13.25 | 12.81 |
| Interest (INR Cr) | 3.07 | 3.48 | 3.33 | 1.63 | 0.99 | 0.58 |
| Pre-tax income (INR Cr) | 0.53 | 0.86 | 1.92 | 2.54 | 3.09 | 3.64 |
| Net income (INR Cr) | 0.19 | 1.55 | 1.09 | 2.26 | 2.30 | 2.68 |
| Borrowings (INR Cr) | 25.32 | 24.99 | 16.15 | 12.87 | 3.87 | 8.88 |
| Shareholders' equity (INR Cr) | 2.64 | 4.20 | 14.20 | 16.46 | 18.76 | 21.44 |
| ROCE (%) | — | 15.19 | 17.64 | 13.67 | 14.90 | 14.92 |
(Source: Screener.in standalone data; equity = equity capital + reserves.) The early history shows a highly leveraged start-up phase (borrowings ~10x equity in FY2016) followed by IPO-funded and cash-flow-funded deleveraging through FY2020. EBITDA margins have trended down from ~18–19% in FY2016 to ~9–10% in FY2024–FY2026, indicating structural pricing or mix pressure.
APPENDIX B — RELATED-PARTY TRANSACTIONS DISCLOSED (FY2026 AOC-2)
| Related party | Relationship | Nature of transaction | Value |
|---|---|---|---|
| Bharatbhai Chokshi | Father of former co-promoter Shalin Chokshi; family holds ~36.74% | Consultancy services to the company | Per note 35 of FY2026 financials |
| Kavita Shalin Chokshi | Wife of Shalin Chokshi | Rent of immovable property (11 months 29 days) | Per note 35 |
| Shalin Patel HUF | MD is Karta | Rent of immovable property | Per note 35 |
| Arvee Speciality Chemicals Pvt Ltd | 100% owned by Patel and Chokshi families; MD is a director | Rent of immovable property | Per note 35 |
| B Chokshi Chem Pvt Ltd | 100% owned by relatives of Shalin Chokshi | Purchase of goods | Per note 35 |
| Praveenkumar Rameshchandra Mishra | Non-executive director | Consultancy services | Per note 35 |
| Archana Praveenkumar Mishra | Relative of director P. R. Mishra | Consultancy services | Per note 35 |
All transactions are stated by the company to be in the ordinary course of business, at arm's length, approved by the Audit Committee, and not material under SEBI LODR Regulation 23.
APPENDIX C — SOURCES CONSULTED
-
Arvee Laboratories (India) Ltd, Annual Report FY2025–26 (incl. AGM Notice, Board's Report, Secretarial Audit, Corporate Governance Report), filed with NSE 3 Sep 2026 — archives.nseindia.com
-
Arvee Laboratories, Outcome of Board Meeting and Unaudited Results for quarter ended 30 June 2026 (7 Aug 2026), incl. segment table and limited review by Nirav Patel & Associates — nsearchives.nseindia.com
-
Arvee Laboratories, Results for half-year ended 30 Sep 2025 (14 Nov 2025) — nsearchives.nseindia.com
-
NSE integrated filings (Ind AS) for FY2025 (9 May 2025) and FY2026 (19 May 2026); prior intimations (3 Feb 2025; 3 May 2026) — nsearchives.nseindia.com
-
NSE circulars on 1:1 bonus issue (7 Oct 2020; 20 Oct 2020) and company bonus/migration filings (24 Aug, 6 Oct, 10 Oct, 15 Oct 2020); re-appointment filing (27 Jun 2022)
-
CRISIL Ratings rationale, 27 Feb 2026 — crisil.com
-
Screener.in company page for ARVEE (financials, ratios, shareholding, announcements), accessed 19 Oct 2026
-
Business Standard / Capital Market, Q4 FY2025 results report (10 May 2025)
-
MoneyWorks4Me, Q4 FY2025 results summary
-
Goodreturns, FY2025 Directors' Report extract
-
IIFL (indiainfoline.com), company summary and board meeting history
-
IPO Central, Chittorgarh, IPO Platform, Samco — IPO details (Feb 2018)
-
Company website www.arveelabs.com (home, infrastructure, product pages)
-
Morningstar, Investing.com, Value Research, Wright Research, Musaffa, Research360, Equentis, IndMoney, Fyers, Torus Digital — market data and profiles
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | DIN | On board since | Background / education / age | Shares held (31 Mar 2026) | FY2026 board attendance | Source |
|---|---|---|---|---|---|---|---|
Shalin Sudhakarbhai Patel | Chairman & Managing Director; Promoter; Executive | 01,779,902 | Promoter in control since 1 Apr 2013; MD re-appointed 27 Jun 2022 | Co-founder/promoter; also director on Shree Rama Multi-Tech Limited (member of its audit and stakeholders committees). Education and age not disclosed in sources reviewed | 40,42,000 (36.68%) | 5/5 | FY2026 Annual Report |
Saurin Ajitbhai Gandhi | Director (Non-Executive, Non-Independent per Corporate Governance report) and Chief Financial Officer | 11,237,690 | 12 Aug 2025 (additional director); confirmed at AGM 24 Sep 2025; re-appointed on rotation at AGM 29 Sep 2026 | M.Com (Accounts & Finance), Gujarat University; ~16 years' experience in accounts, finance and liaison; born 23 Aug 1983 (age 43) | 4,000 | 2/2 | FY2026 AGM Notice |
Praveen Kumar Rameshchandra Mishra | Non-Executive, Non-Independent Director | 10,687,679 | Not stated in sources reviewed (DIN series suggests 2024 appointment) | Not disclosed; provides consultancy services to the company (related-party transaction) | 0 | 5/5 | FY2026 Annual Report |
Sachin Kanwarlal Kansal | Independent Director; Chair of Audit Committee | 03,566,139 | 1 Oct 2021; re-appointed for second term 1 Oct 2026 – 30 Sep 2031 | B.Com, Chartered Accountant; experience in accounts, taxation, legal and administration; born 13 Sep 1987 (age 39) | 0 | 5/5 | FY2026 AGM Notice |
Shalini Hitesh Jalan | Independent Director | 09,620,065 | 26 May 2022; re-appointed for second term 26 May 2027 – 25 May 2032 | B.A.; experience in computers; born 30 Sep 1982 (age 44); also director of Aprameya Engineering Limited (NSE-listed) and Air Control Chemical and Engineering Company Limited | 0 | 5/5 | FY2026 AGM Notice |
Neetu Rishi Jalan | Independent Director; Audit Committee member | 08,719,470 | Not stated in sources reviewed | Not disclosed; holds one other listed directorship | 0 | 5/5 | FY2026 Annual Report |
Shalin Bharat Chokshi (former) | Whole-Time Director; Co-Promoter | 00,191,903 | Promoter in control since 1 Apr 2013; ceased 30 Jun 2025 | Co-founder/promoter; family continues to hold ~36.7% | 0 (personally, at 31 Mar 2026) | 2/5 | FY2026 Annual Report |
Governance Detail
| Role | Name | Note |
|---|---|---|
Managing Director / Chairman | Shalin Sudhakarbhai Patel | Combined Chair and MD |
Chief Financial Officer | Saurin Ajitbhai Gandhi | Also a board director |
Company Secretary & Compliance Officer | Not identified in the excerpts reviewed | — |
“—” = not publicly disclosed.
Executive Leadership Team
| Person | Component | Amount | Source |
|---|---|---|---|
Saurin Ajitbhai Gandhi | Remuneration last drawn | INR 1,512 thousand (INR 15.12 lakh) | FY2026 AGM Notice |
Sachin Kanwarlal Kansal | Remuneration / sitting fees last drawn | INR 70 thousand | FY2026 AGM Notice |
Shalini Hitesh Jalan | Remuneration / sitting fees last drawn | INR 70 thousand | FY2026 AGM Notice |
Shalin Sudhakarbhai Patel (MD) | Salary / bonus / stock / total | — | — |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
30 Jun 2025 | Shalin Bharat Chokshi (co-promoter, WTD) resigned | Ends dual-promoter executive leadership; Chokshi family retains its ~36.7% stake and continues to transact with the company (consultancy by Bharatbhai Chokshi; rent from Kavita Chokshi; purchases from B Chokshi Chem Pvt Ltd). Secretarial audit flagged late disclosure of the resignation |
12 Aug 2025 | Saurin Gandhi joined board | Adds finance capability; he is also CFO |
29 Sep 2026 | Re-appointment of Sachin Kansal (from 1 Oct 2026) and Shalini Jalan (from 26 May 2027) for second terms approved at AGM | Continuity of independent directors |
Shareholding Trend
| Holder category | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|
Promoters & promoter group (%) | 73.50 | 73.50 | 73.50 | 73.50 | 73.50 |
Public (%) | 26.50 | 26.50 | 26.50 | 26.50 | 26.50 |
FIIs (%) | 0 | 0 | 0 | 0 | 0 |
DIIs / mutual funds (%) | 0 | 0 | 0 | 0 | 0 |
Number of shareholders | 1,416 | 1,576 | 1,505 | 1,638 | 1,947 |
Competitive Landscape
Competitors by Segment
| Product family | Competitor set (analyst identification) | Basis of overlap |
|---|---|---|
Polymer modifiers (SIPA salts, DMS, SIPHE) | Chinese SIPA/DMS producers (individually small, numerous); other Indian specialty chemical makers of sulfonated aromatics; captive production by large polyester integrators | Same molecules; commodity-like pricing set largely by Chinese supply |
Contrast media intermediates (5-NIPA, 5-AIPA, DNBA, DABA families) | Chinese and Indian contrast-media intermediate producers; captive/affiliated supply chains of the major iodinated contrast-agent originators (GE HealthCare, Bayer, Bracco, Guerbet are the principal global contrast-agent companies) | Upstream of iodinated contrast APIs (iohexol, iopamidol, iodixanol, diatrizoate class) |
Drug intermediates (thiophenes, 4-aminopyridine, nitro-chlorobenzoic acids) | Jubilant Ingrevia (major pyridine and pyridine-derivative producer); Aarti Industries (nitro-aromatics, benzenoids); Hikal, Ami Organics, Laxmi Organic and similar Indian intermediate/CDMO players; Chinese thiophene derivative producers | Overlapping chemistries and customer base (Indian API makers) |
Key Competitors
| # | Company | Listing | Relevance to Arvee |
|---|---|---|---|
| 1 | Jubilant Ingrevia Ltd | NSE/BSE | Pyridine and pyridine derivatives (overlap with 4-aminopyridine) |
| 2 | Aarti Industries Ltd | NSE/BSE | Large nitration and reduction-chemistry platform (overlap with nitro-aromatic intermediates) |
| 3 | Hikal Ltd | NSE/BSE | Pharma intermediates / CDMO |
| 4 | Ami Organics Ltd | NSE/BSE | Advanced pharma intermediates |
| 5 | Laxmi Organic Industries Ltd | NSE/BSE | Specialty intermediates |
| 6 | Vinati Organics Ltd | NSE/BSE | Niche aromatic specialty chemicals and polymer additives (model of a niche-molecule leader) |
| 7 | GE HealthCare / Bayer / Bracco / Guerbet | Various | Principal global iodinated contrast-agent producers — ultimate demand setters (and potential captive competitors) for contrast intermediates |
| 8 | Chinese SIPA/DMS and nitro-isophthalic producers (unnamed) | Various | Price-setting competitors in polymer modifiers and contrast intermediates |
| 9 | Other Gujarat-based SME intermediates makers | Various | Similar scale and chemistry |
| 10 | Captive production by large polyester integrators | Various | Potential self-supply of SIPA/DMS |
Competitor Detail
| Metric | Arvee Laboratories |
|---|---|
Revenue FY2026 | INR 31.5 crore |
Revenue growth FY2026 | −18.1% |
EBITDA margin FY2026 | 10.1% |
Net margin FY2026 | 8.0% (tax-credit aided) |
R&D intensity FY2026 | 0% (Nil reported) |
P/E (Oct 2026) | ~57x TTM |



